⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRNX News
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
CRNX
Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight
globenewswire.com
VNDA
GRFS
BHC
RDHL
MRK
TEVA
PFE
SNY
LLY
ABBV
AZN
CRCT
SPRO
CRNX
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
globenewswire.com
CRNX
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer
globenewswire.com
CRNX
Form 8-K
sec.gov
CRNX
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
globenewswire.com
CRNX
Crinetics Pharmaceuticals Solicita Autorização de Comercialização de Palsonify™ (Paltusotina) no Brasil para Tratamento de Acromegalia
globenewswire.com
CRNX
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
globenewswire.com
CRNX
Form 8-K
sec.gov
CRNX
Form 8-K
sec.gov
CRNX